European Microbiome Innovation for Health
Created in 2021
- BETA
Up & running (A)
Existing signals show a regular activity Social networks
90 1,636 1,636Activities
Entity types
Location
Paris, France
Paris
France
Employees
Scale: 51-200
Estimated: 3
Engaged corporates
11
2 7Added in Motherbase
1 year, 9 months ago
biotech Value proposition
Leading the way in Europe to bring microbiome-based innovations to market
The Alliance Promotion Microbiote is becoming the European Microbiome Innovation for Health: a major step towards structuring the European microbiome excellence sector.
European Microbiome Innovation for Health (EMIH) brings together innovative leading European stakeholders dedicated to advancing the microbiome industry.
EMIH gathers more than 20 key players from public and private sectors: Bioaster, Biocodex, Biofortis, Biose Industrie, Cynbiome, Eligo Bioscience, Pelican Health, GMT, INRAE, Ferring Pharmaceuticals, Lallemand, Luxia, Lyonbiopole Auvergne-Rhône-Alpes, MaaT Pharma, Medicen, Microbiome Fundation, Nexbiome, Novobiome, PolePharma, Seventure Partners, Skyepharma supporting each other’s efforts to develop tomorrow’s medicine based on microbiome diagnostic and therapeutic innovations.
The goal of the EMIH is to promote medical innovation, based on the microbiota, as one of the public health priorities within the European Union. Its members are committed to developing advances in therapeutic, diagnostics and medical bioproduction based on the microbiota, in the field of human health, through a framework meeting the highest quality standards and also allowing economic balance, in order to maintain therapeutic innovation.
EMIH is collectively building a dynamic ecosystem to advance medical innovation centered on the microbiota, prioritizing public health within the EU and addressing unmet medical needs to enhance the quality of life for millions of patients.
microbiome, research, clinical development, public, private, microbiota, and R&DOriginal language
Leading the way in Europe to bring microbiome-based innovations to market
The Alliance Promotion Microbiote is becoming the European Microbiome Innovation for Health: a major step towards structuring the European microbiome excellence sector.
European Microbiome Innovation for Health (EMIH) brings together innovative leading European stakeholders dedicated to advancing the microbiome industry.
EMIH gathers more than 20 key players from public and private sectors: Bioaster, Biocodex, Biofortis, Biose Industrie, Cynbiome, Eligo Bioscience, Pelican Health, GMT, INRAE, Ferring Pharmaceuticals, Lallemand, Luxia, Lyonbiopole Auvergne-Rhône-Alpes, MaaT Pharma, Medicen, Microbiome Fundation, Nexbiome, Novobiome, PolePharma, Seventure Partners, Skyepharma supporting each other’s efforts to develop tomorrow’s medicine based on microbiome diagnostic and therapeutic innovations.
The goal of the EMIH is to promote medical innovation, based on the microbiota, as one of the public health priorities within the European Union. Its members are committed to developing advances in therapeutic, diagnostics and medical bioproduction based on the microbiota, in the field of human health, through a framework meeting the highest quality standards and also allowing economic balance, in order to maintain therapeutic innovation.
EMIH is collectively building a dynamic ecosystem to advance medical innovation centered on the microbiota, prioritizing public health within the EU and addressing unmet medical needs to enhance the quality of life for millions of patients.
EMIH - Driving Microbiome Industry in Europe
EMIH accelerates microbiome research, attracts investment & promotes innovative therapies in Europe. Join us to position Europe as a global microbiome leader.
https://europeanmicrobiome.org/
| Corporate | Type | Tweets | Articles | |
|---|---|---|---|---|
 Lyonbiopôle Auvergne-Rhône-Alpes Public business cluster, Biotechnology, French Cluster, Biotechnology Research | Lyonbiopôle Auvergne-Rhône-Alpes Public business cluster, Biotechnology, French Cluster, Biotechnology Research | Other 17 Dec 2024 | | |